You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

relapsed/metastatic

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Esophageal Squamous Cell Carcinoma Trial in Hangzhou (Cadonilimab combined Anlotinib)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Cadonilimab combined Anlotinib
  • Hangzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Aug 6, 2023

Squamous Cell Carcinoma of Head and Neck Trial in Shanghai (Camrelizumab+cetuximab+chemo)

Not yet recruiting
  • Squamous Cell Carcinoma of Head and Neck
  • Shanghai, China
    Fudan University
Jan 4, 2023

EBV-positive Nasopharyngeal Carcinoma Trial in Guangzhou (Cohort A: 3.0x10^6 CAR-T cells/kg, Cohort B: 9.0x10^6CAR-T cells/kg,

Not yet recruiting
  • EBV-positive Nasopharyngeal Carcinoma
  • Cohort A: 3.0x10^6 CAR-T cells/kg
  • +2 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
May 16, 2023

Head and Neck Squamous Cell Carcinoma Trial (Carrilizumab, bevacizumab,capecitabine)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Carrilizumab, bevacizumab,capecitabine
  • (no location specified)
Jul 20, 2023

NSCLC Trial (Tirelizumab;Chemotherapy monotherapy)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Tirelizumab；Chemotherapy monotherapy
  • (no location specified)
Jul 27, 2023

A Real-world Study of Inetetamab for First-line Treatment of MBC

Not yet recruiting
  • Breast Cancer
  • Real-world Study
  • (no location specified)
Aug 6, 2023

Solid Tumor, Breast Cancer, Pancreatic Cancer Trial in United States (SON-DP)

Recruiting
  • Solid Tumor
  • +4 more
  • Gilbert, Arizona
  • +4 more
Aug 4, 2023

Triple-negative Breast Cancer Trial in Shanghai (chidamide, camrelizumab, carboplatin)

Not yet recruiting
  • Triple-negative Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jun 25, 2022

Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Squamous Cell Carcinoma Trial in China (TQB2618 injection,

Not yet recruiting
  • Recurrent Squamous Cell Carcinoma of the Head and Neck
  • Metastatic Squamous Cell Carcinoma
  • TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin
  • Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin
  • Lanzhou, Gansu, China
  • +11 more
Mar 23, 2023

Nasopharyngeal Carcinoma Trial in Xuzhou (BGT007 Cell Injection, Fludarabine, cyclophosphamide)

Recruiting
  • Nasopharyngeal Carcinoma
  • BGT007 Cell Injection
  • +2 more
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Dec 14, 2022

Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Trial (SBRT, Cadonilimab)

Not yet recruiting
  • Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
  • (no location specified)
Feb 8, 2023

Squamous Cell Carcinoma of the Skin Trial in Zhengzhou (Carrilizumab with albumin-binding paclitaxel)

Not yet recruiting
  • Squamous Cell Carcinoma of the Skin
  • Carrilizumab with albumin-binding paclitaxel
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
May 23, 2023

Germ Cell Tumor, Non-seminomatous Germ Cell Tumor, Ovarian Germ Cell Tumor Trial in Indianapolis (Etoposide)

Recruiting
  • Germ Cell Tumor
  • +2 more
  • Indianapolis, Indiana
    Indiana University Melvin & Bren Simon Cancer Center
Dec 20, 2022

Breast Cancer Trial in Shanghai (Chidamide, Abemaciclib, Fulvestrant)

Recruiting
  • Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jul 31, 2022

Metastatic Colorectal Cancer Trial (CA102N, TAS-102, Bevacizumab)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • (no location specified)
Sep 8, 2023

Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer Trial

Not yet recruiting
  • Hormone Receptor-positive Breast Cancer
  • +2 more
  • Nashville, Tennessee
    Sarah Cannon Research Institute
Oct 5, 2022

Glioma, Solid Tumor Trial in Beijing (GNC-039)

Recruiting
  • Glioma
  • Solid Tumor
  • Beijing, Beijing, China
  • +5 more
Jan 12, 2023

NSCLC, Metastatic Colorectal Carcinoma, Refractory Melanoma Trial in Pittsburgh (Pixatimod, Nivolumab, Cyclophosphamide (low

Recruiting
  • NSCLC
  • +2 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Mar 28, 2022

Triple-negative Breast Cancer Trial in Shanghai (Chidamide combined with Cisplatin)

Recruiting
  • Triple-negative Breast Cancer
  • Chidamide combined with Cisplatin
  • Shanghai, China
  • +1 more
Apr 19, 2022

Colorectal Cancer Trial in United States (GCC19CART)

Recruiting
  • Colorectal Cancer
  • San Francisco, California
  • +4 more
Dec 20, 2022

Solid Tumor Metastatic Cancer Advanced Cancer Trial (TJ210001)

Available
  • Solid Tumor Metastatic Cancer Advanced Cancer
  • (no location specified)
Aug 19, 2022

HPV Associated Cancers Trial in New York, Houston (TGN-S11, Pembrolizumab)

Not yet recruiting
  • HPV Associated Cancers
  • New York, New York
  • +1 more
Apr 25, 2023

Breast Cancer Trial in China (TQB2102 for injection)

Not yet recruiting
  • Breast Cancer
  • TQB2102 for injection
  • Hefei, Anhui, China
  • +20 more
Nov 1, 2023

Cholangiocarcinoma Metastatic Trial in China (TT-00420 (tinengotinib))

Not yet recruiting
  • Cholangiocarcinoma Metastatic
  • TT-00420 (tinengotinib)
  • Guangzhou, Guangdong, China
  • +6 more
Sep 26, 2023

Advanced Cancer, Metastatic Cancer, Tumors Trial in Atlanta, Chapel Hill (MRX-2843)

Recruiting
  • Advanced Cancer
  • +5 more
  • Atlanta, Georgia
  • +1 more
Mar 4, 2022